Menu
ncarol.com
  • Home
  • Books
  • Health
  • Book Release
  • Manufacturing
  • Business
  • Financial
  • Real Estate
  • Marketing
ncarol.com

Blaming Patients: How Failed Treatments Fuel a $51 Billion Brain Device Industry
ncarol.com/10291948

Trending...
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
CCHR's New Report Exposes Dangerous Devices
CCHR's New Report Exposes Dangerous Neurological Interventions Being Pushed on Veterans, Children, and the Vulnerable

LOS ANGELES - ncarol.com -- The Citizens Commission on Human Rights International (CCHR), a leading mental health industry watchdog, has released a damning report detailing how psychiatry is blaming patients—rather than failed treatments—to justify a surge in brain stimulation interventions. "When psychiatric drugs and therapy don't work, psychiatry rarely blames the treatment—it blames the patient, saying they are 'treatment-resistant,'" said Jan Eastgate, President of CCHR International. "'Treatment-resistant' isn't a diagnosis—it's a deflection. And it's being used to push invasive procedures like Electroconvulsive Therapy (ECT), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and Transcranial Magnetic Stimulation (TMS)."

These brain stimulation devices were "cleared" by the Food and Drug Administration (FDA) or approved under Humanitarian Device Exemptions, bypassing the rigorous testing normally required of most medical devices. Many were greenlighted based on the device delivering ECT—a practice known for causing brain damage, memory loss, and even death[1].

Even industry insiders acknowledge concerns. "The precise physiological mechanisms of DBS are not yet fully understood," admits one clinical review.[2]  A professor of psychiatry at Brown University's Alpert Medical School, put it more starkly: "This really is a kind of mind control."[3]

The term "treatment-resistant" is a psychiatric sleight of hand, Eastgate says, now used to justify a global neurostimulation industry projected to hit $51 billion by 2030. Labeling up to 60% of psychiatric patients as "resistant" creates a false pretext for experimental interventions.[4] Meanwhile, 25% of patients develop psychotropic drug tolerance within weeks, prompting ever-riskier "solutions."[5]

Electroshock: Psychiatry's Recycled Blunder

ECT involves sending up to 460 volts through the brain to trigger seizures. Contrary to PR spin, Eastgate says, experts report modern ECT is no safer—voltage levels are higher than when broken bones were common due to convulsions.
  • FDA Loophole: Grandfathered in without clinical trials in 1976. In 2018, the FDA reclassified some ECT uses as "low risk," even for children as young as 13. Over 2,400 public comments opposed this.
  • Global Condemnation: The World Health Organization and United Nations consider ECT on children or the non-consenting a form of torture.[6]
  • Medical Harm: Neurologists equate ECT's effects to traumatic brain injury.[7] Patients are 44 times more likely to die by suicide than the general population. One in 15 ECT patients face life-threatening cardiac issues.[8]
  • Financial Cost: A $3–5.4 billion industry. Medicaid spent $9 million on ECT in 2023 in 27 states.[9] The VA and Department of Defense have administered it to veterans and children under age five.[10]

Deep Brain Stimulation: Electrodes are surgically implanted into the brain, powered by a device in the chest.
  • FDA Fast Track: Approved via Humanitarian Device Exemption for OCD in 2009 without efficacy data.
  • Harms: Stroke, hemorrhage, hallucinations, sexual dysfunction, apathy, and suicide attempts.[11]
  • Patient Testimonies: Participants in failed DBS trials report cognitive decline and emotional deterioration.[12]

Vagus Nerve Stimulation: Electrical stimulation delivered via electrodes wrapped around the vagus nerve.
  • FDA: Approved in 2005 for "treatment-resistant depression" despite lacking robust evidence.
  • Risks: Nerve damage, infection, hoarseness, breathing difficulty. The FDA has logged over 10,000 complaints involving death, injury, or device malfunction.[13]
  • Cost: Averaging $30,000+.

Transcranial Magnetic Stimulation: Magnetic pulses are aimed at the brain over six weeks.
  • Youth Approval: Cleared in 2008 for adults, and in 2024 for adolescents as young as 15.
  • Side Effects: "Brain fog," seizures, mood swings. One patient said: "This treatment destroyed my life… It gave me false hope."[14]
  • Price Tag: Up to $300 per session; full courses can reach $15,000.

Despite the sophistication of these procedures, there is still no objective medical test to diagnose any psychiatric disorder. No blood test. No brain scan. No biomarker.[15]

More on ncarol.com
  • RemoteBridge Names Dr. John N. Just, Ed.D. Chief Executive Officer
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support

Dr. Thomas Insel, former director of the National Institute for Mental Health advised: "Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM [Diagnostic and Statistical Manual of Mental Disorders] diagnoses are based on a consensus… not any objective laboratory measure."[16]

"It's not the patient that's resistant—it's the system that's resistant to accountability," Eastgate said. "In any other field, if the intervention failed, the treatment would be reevaluated. But psychiatry doubles down, pushing more dangerous interventions instead."

CCHR urges policy makers to: End all use of ECT and brain stimulation devices for treatment of mental issues, and end ECT's role as a predicate device for newer technologies. And support humane, non-invasive, non-drug, non-brain stimulation solutions that respect patient dignity and avoid neurological and other physical harm.

CCHR, established in 1969 by the Church of Scientology and psychiatrist Dr. Thomas Szasz has a record of reforms that include banning lethal Deep Sleep Treatment, outlawing ECT use on children in several U.S. states, and securing global recognition for patient rights. Today, the United Nations and WHO echo what CCHR has long fought for: coercion has no place in mental health care.

Sources:

[1] FDA, Final Rule on Electroconvulsive Therapy Devices, Federal Register, Dec. 26, 2018; WHO-OHCHR, "Guidance on Mental Health, Human Rights and Legislation," 9 Oct. 2023, p. 58, www.ohchr.org/sites/default/files/documents/publications/WHO-OHCHR-Mental-health-human-rights-and-legislation_web.pdf

[2] Lavanya P. Sharma, et. al, "Deep brain stimulation – A primer for psychiatrists," Asian Journal of Psychiatry, Vol. 104, Feb. 2025

[3] Lavanya P. Sharma, et. al, "Deep brain stimulation – A primer for psychiatrists," Asian Journal of Psychiatry, Vol. 104, Feb. 2025

[4] "Treatment resistance in psychiatry: state of the art and new directions," Mol Psychiatry, July 2021, pmc.ncbi.nlm.nih.gov/articles/PMC8960394/#fn-group1

[5] pmc.ncbi.nlm.nih.gov/articles/PMC9332474/

[6] WHO- OHCHR, "Guidance on Mental Health, Human Rights and Legislation," 9 Oct. 2023, pp. 15, 58 and 59; www.cchrint.org/2023/09/18/who-guideline-condemns-coercive-psychiatric-practices/

[7] "Electroconvulsive Shock Therapy Lawsuit – What You Should Know About ECT," www.wisnerbaum.com/defective-medical-device-injuries/ect/

[8] www.cchrint.org/2024/11/08/veterans-day-cchr-calls-for-safeguards/, Peter Simons, "ECT Does Not Seem to Prevent Suicide," Mad In America, 17 Feb. 2023, www.madinamerica.com/2023/02/ect-does-not-seem-to-prevent-suicide/

More on ncarol.com
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
  • Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
  • Nadi Plumbing Leads Charlotte in Private Fire Hydrant Services, Eyes Regional Expansion

[9] www.cchrint.org/2024/08/23/the-collapse-of-electroshock/ Based on Freedom of Information Requests to 27 states

[10] www.cchrint.org/2018/10/12/veterans-get-damaging-mental-health-deal/; Tricare Encounter Data (TED) Non-Institutional (Outpatient) for Purchased Care claims, Data Extract as of 10/21/2016, Data received from CCHR International Freedom of Information Request, 2016

[11] "Brain Stimulation Therapies," NIMH, www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml, accessed 21 Feb. 2011; Dr. Ananya Mandal, MD, "Deep Brain Stimulation Side Effects," News Medical Life Sciences, 22 July 2023, www.news-medical.net/health/Deep-Brain-Stimulation-Side-Effects.aspx

[12] Danielle Egan, "Adverse Effects: The Perils of Deep Brain Stimulation for Depression," Mad in America, 24 Sept. 2015

[13] www.hg.org/legal-articles/patients-with-complications-from-cyberonics-vns-therapy-systems-may-qualify-to-file-a-lawsuit-49467

[14] FDA MAUDE report, Neurostar TMS, 07/14/2021, www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=15283600&pc=OBP

[15] www.sciencedaily.com/releases/2020/08/200817104247.htm

[16] psychrights.org/2013/130429NIMHTransformingDiagnosis.htm

Contact
CCHR International
***@cchr.org


Source: Citizens Commission on Human Rights International
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • STEM For Kids® Unveil Turn-Key "Screen-Smart" Solution to Bridge Teacher Preparedness Gaps in Texas
  • Award-Winning Couture Master Perfumer JoAnne Bassett Launches All-Natural DIY Perfume Making Kits
  • Couture Master Perfumer JoAnne Bassett Offers Rare Opportunity to Acquire 70 Formula Perfume Codex
  • Slotozilla Reports Strong Growth in Q2 2026
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • New Book Helps Educators Navigate AI in the Classroom While Keeping Humans in Charge
  • San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
  • LifeTime Asset & Tax Management Named on the 2026 Inc. 5000 List
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • Pastor Miguel Bustillos Brings Deliverance and Exorcism Ministry Conference to Durham, NC
  • TOLI CORPORATION's President Visits U.S. to Celebrate Partnerships and Support North American Market
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living
_catLbl0 _catLbl1

Popular on ncarol.com

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 315
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 138
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home - 121
  • $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC) - 120
  • Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services - 110
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings - 106
  • RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation - 105
  • UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement - 102
  • 'Reflections: Enlightening Insights Into the Divine Mystery' — The Latest Book by Philosopher Steven Colborne - 101
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism

Similar on ncarol.com

  • Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
  • When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • The Sharon at SouthPark Breaks Ground on $178 Million Expansion
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute